Quick Answer
Actinium Pharmaceuticals, Inc. reported Cash and Equivalents of $48.00 million for fiscal year 2025.
Actinium Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $48.00M | -34.2% |
| 2024 | $72.90M | -4.9% |
| 2023 | $76.68M | -29.6% |
| 2022 | $108.91M | +39.9% |
| 2021 | $77.83M | +22.4% |
| 2020 | $63.56M | +586.8% |
| 2019 | $9.25M | -32.3% |
| 2018 | $13.67M | -21.4% |
| 2017 | $17.40M | -15.2% |
| 2016 | $20.52M | -20.0% |
| 2015 | $25.64M | +282.3% |
| 2014 | $6.71M | +21.2% |
| 2013 | $5.53M | -1.5% |
| 2012 | $5.62M | -1.5% |
| 2011 | $5.70M | +2808.1% |
| 2010 | $196.1K | +9142.9% |
| 2009 | $2.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $53.39M | -32.1% | -10.9% |
| June 30, 2025 | $59.93M | -30.3% | -8.3% |
| March 31, 2025 | $65.33M | -22.3% | -10.4% |
| December 31, 2024 | $72.90M | -4.9% | -7.3% |
| September 30, 2024 | $78.66M | -5.2% | -8.6% |
| June 30, 2024 | $86.04M | -5.7% | +2.4% |
| March 31, 2024 | $84.06M | -11.1% | +9.6% |
| December 31, 2023 | $76.68M | -29.6% | -7.6% |
- Actinium Pharmaceuticals, Inc. showed a decrease of -34.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Actinium Pharmaceuticals, Inc.’s cash and equivalents has grown by 2261822.7% (from $2.1 thousand to $48.00 million).
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: